Artwork

内容由Healio提供。所有播客内容(包括剧集、图形和播客描述)均由 Healio 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

DME/Retina Edition: Top Headlines for Week of July 8, 2024

10:22
 
分享
 

Manage episode 428373684 series 3560281
内容由Healio提供。所有播客内容(包括剧集、图形和播客描述)均由 Healio 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

In this edition, FDA approves Vabysmo prefilled syringe for retinal diseases, 4D Molecular Therapeutics updates on retinal disease candidates and more. Read the full coverage here:

FDA approves Vabysmo prefilled syringe for retinal diseases

VIDEO: 4D Molecular Therapeutics shares update on retinal disease candidates

FDA approves Eylea biosimilar FYB203/Ahzantive

VIDEO: Oral therapy improves central subfield thickness in DME in early-stage study

ANI Pharmaceuticals to acquire Alimera Sciences

References:

Agrawal R. RZ402: Initial results from a phase 2 study of a novel, orally administered PKal inhibitor in patients with DME. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Healio Interviews

Press Release

Press Release

Press Release

Editor's note: At the 1:35 mark, we mention that Vabysmo will be available later this year. This specifically applies to Vabysmo pre-filled syringe. There is a currently available formulation already on the market.

  continue reading

119集单集

Artwork
icon分享
 
Manage episode 428373684 series 3560281
内容由Healio提供。所有播客内容(包括剧集、图形和播客描述)均由 Healio 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

In this edition, FDA approves Vabysmo prefilled syringe for retinal diseases, 4D Molecular Therapeutics updates on retinal disease candidates and more. Read the full coverage here:

FDA approves Vabysmo prefilled syringe for retinal diseases

VIDEO: 4D Molecular Therapeutics shares update on retinal disease candidates

FDA approves Eylea biosimilar FYB203/Ahzantive

VIDEO: Oral therapy improves central subfield thickness in DME in early-stage study

ANI Pharmaceuticals to acquire Alimera Sciences

References:

Agrawal R. RZ402: Initial results from a phase 2 study of a novel, orally administered PKal inhibitor in patients with DME. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Healio Interviews

Press Release

Press Release

Press Release

Editor's note: At the 1:35 mark, we mention that Vabysmo will be available later this year. This specifically applies to Vabysmo pre-filled syringe. There is a currently available formulation already on the market.

  continue reading

119集单集

Todos os episódios

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南